sevacizumab

A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, sevacizumab specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival. Check for active clinical trials using this agent. (NCI Thesaurus)

Related Posts

Award Winning Physicians

Our Physicians work for you, ensuring the highest standard of care.

Learn More